Sequel与Senseonics达成了一年期CGM系统协议-动脉网

Sequel strikes deal with Senseonics for one-year CGM system

Medical Device Network 等信源发布 2025-04-29 15:46



可切换为仅中文







The integration of Sequel’s twiist automated insulin delivery system with Senseonics one-year CGM system is expected to give T1D patients more control over their diabetes care management. Image credit: photohasan via Shutterstock.

Sequel的twiist自动胰岛素输送系统与Senseonics一年期CGM系统的整合预计将使1型糖尿病患者在糖尿病护理管理上获得更多的控制权。图片来源：photohasan通过Shutterstock。

Sequel and Senseonics are teaming up on a development agreement aimed at transforming diabetes care.

Sequel和Senseonics正在就一项旨在改变糖尿病护理的发展协议进行合作。

The collaboration will involve the integration of Sequel’s twiist Automated Insulin Delivery (AID) system with Senseonics’ Eversense 365, the first one-year continuous glucose monitoring (CGM) system.

此次合作将涉及Sequel的twiist自动胰岛素输送（AID）系统与Senseonics的Eversense 365（首个一年期连续血糖监测（CGM）系统）的整合。

With Sequel’s twiist set to become the first AID system compatible with Eversense 365, the companies said the move will provide type 1 diabetes patients with increased flexibility and personalisation in managing their condition.

随着Sequel的twiist将成为首个与Eversense 365兼容的AID系统，这些公司表示，此举将为1型糖尿病患者提供更大的灵活性和个性化管理方案。

Eversense 365 went on sale in the US in October 2024 following approval from the US Food and Drug Administration (FDA) in September for continually measuring glucose levels for up to one year in diabetes patients aged 18 and above. The system is indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions..

Eversense 365 在 2024 年 10 月于美国上市，此前该产品于 9 月获得美国食品和药物管理局 (FDA) 批准，用于持续测量 18 岁及以上糖尿病患者的血糖水平，最长可达一年。该系统旨在替代指尖血糖测量，为糖尿病治疗决策提供依据。

According to Senseonics, which filed for

根据Senseonics公司提交的文件，该公司已经申请了

European CE mark registration

欧盟CE标志注册

for the implantable device in February, Eversense 365 ideates on the traditional short-term CGMs, offering advantages to type 1 diabetes patients with its one-year sensor lifespan, minimal data interruptions, and fewer wasted sensors.

今年 2 月，Eversense 365 这款可植入设备以传统的短期 CGM 为基础进行创新，凭借其一年的传感器使用寿命、极少的数据中断以及更少的传感器浪费，为 1 型糖尿病患者提供了更多益处。

Senseonics president and CEO Tim Goodnow said the integration with Sequel, which is expected to be available by Q3 2025, would result in a “significant step forward” in diabetes care.

Senseonics总裁兼首席执行官蒂姆·古德诺表示，与Sequel的整合预计将在2025年第三季度实现，这将使糖尿病护理“向前迈出重要一步”。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预料？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由环球数据

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

“People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management,” Goodnow explained.

“选择我们一年期CGM传感器的便捷性和易用性的糖尿病患者一直在等待一个兼容的AID系统来加强他们的糖尿病管理，”古德诺解释说。

“The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies to simplify diabetes management, providing users with an AID solution that unlocks the full experience of our year-long CGM technology.”

“Eversense 和 twiist 的协同作用将为糖尿病患者提供我们最新的先进泵、算法和传感器技术，简化糖尿病管理，为用户提供一个充分利用我们全年动态血糖监测技术的 AID 解决方案。”

According to GlobalData analysis, the overall global diabetes care market is estimated to reach a valuation of $44bn by 2033, up from $25bn in 2023.

根据 GlobalData 的分析，全球糖尿病护理市场的总体估值预计将从 2023 年的 250 亿美元增长到 2033 年的 440 亿美元。

Elsewhere in the diabetes space, Abbott recently reported a

在糖尿病领域的其他方面，Abbott公司最近报告了

27% uptick in diabetes device sales in Q1 2025, bringing diabetes sales in the US alone to $748m

2025年第一季度糖尿病设备销售额增长27%，仅美国的糖尿病销售额就达到7.48亿美元。

compared to the $1.08bn generated internationally for its Diabetes Care unit. Last year, the device giant opened a

相比其糖尿病护理部门在国际上产生的 10.8 亿美元。去年，这家设备巨头开设了

new manufacturing facility in Ireland

爱尔兰的新制造设施

focused on the global manufacturing of sensors for its CGM diabetes devices.